Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (201-210 of 441) with videos related to

Pageof 45
Sort By:
World Journal of Gastroenterology|May 20, 2015
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC studyBenjamin Terrier, Nathanael Lapidus, Stanislas Pol, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 5, 2017
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assaysJohannes Vermehren, Marc Bourlière, Stanislas Pol, et al.
The Journal of Infectious Diseases|June 6, 2008
Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver diseasePatrick Soussan, Jonathan Pol, Florianne Garreau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 19, 2005
Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virusLaurent Aaron, Pascal Lebray, Marie-Alexandra Alyanakian, et al.
BMC Infectious Diseases|December 17, 2009
Hepatic profile analyses of tipranavir in Phase II and III clinical trialsJaromir Mikl, Mark S Sulkowski, Yves Benhamou, et al.
The Journal of Infection|January 1, 2014
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral responseEvguenia Krastinova, Firouzé Bani-Sadr, Delphine Fromentin, et al.
AIDS (London, England)|June 6, 2008
Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patientsFirouzé Bani-Sadr, Patrick Miailhes, Eric Rosenthal, et al.
European Radiology|August 15, 2019
Can we differentiate HIV-associated obliterative portopathy from liver cirrhosis using MRI?Esther Chouraqui, Laura Leguilloux, Anthony Dohan, et al.
Medicine|March 18, 2016
Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency VirusClémence Hollande, Vincent Mallet, Stéphane Darbeda, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2008
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factorsFirouzé Bani-Sadr, Nathanael Lapidus, Pierre Bedossa, et al.
Pageof 45

Showing results (201-210 of 441) with videos related to

Sort By:
Pageof 45
World Journal of Gastroenterology|May 20, 2015
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC studyBenjamin Terrier, Nathanael Lapidus, Stanislas Pol, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 5, 2017
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assaysJohannes Vermehren, Marc Bourlière, Stanislas Pol, et al.
The Journal of Infectious Diseases|June 6, 2008
Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver diseasePatrick Soussan, Jonathan Pol, Florianne Garreau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 19, 2005
Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virusLaurent Aaron, Pascal Lebray, Marie-Alexandra Alyanakian, et al.
BMC Infectious Diseases|December 17, 2009
Hepatic profile analyses of tipranavir in Phase II and III clinical trialsJaromir Mikl, Mark S Sulkowski, Yves Benhamou, et al.
The Journal of Infection|January 1, 2014
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral responseEvguenia Krastinova, Firouzé Bani-Sadr, Delphine Fromentin, et al.
AIDS (London, England)|June 6, 2008
Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patientsFirouzé Bani-Sadr, Patrick Miailhes, Eric Rosenthal, et al.
European Radiology|August 15, 2019
Can we differentiate HIV-associated obliterative portopathy from liver cirrhosis using MRI?Esther Chouraqui, Laura Leguilloux, Anthony Dohan, et al.
Medicine|March 18, 2016
Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency VirusClémence Hollande, Vincent Mallet, Stéphane Darbeda, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2008
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factorsFirouzé Bani-Sadr, Nathanael Lapidus, Pierre Bedossa, et al.
Pageof 45